# OnCo record lch-single-system (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/lch-single-system/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "lch-single-system" ;
  schema:name "Single-system Langerhans cell histiocytosis (bone, skin or one other organ)"@en ;
  schema:alternateName "Single-system LCH"@en, "Eosinophilic granuloma"@en, "Unifocal bone LCH"@en, "Skin-only LCH"@en, "Pulmonary Langerhans cell histiocytosis (adult smokers)"@en ;
  schema:description "Single-system Langerhans cell histiocytosis is the milder form of this rare histiocytosis, in which the abnormal immune cells affect only one organ, usually a bone or the skin, in a child or young adult. Single bone lesions often heal after biopsy or curettage, skin disease may fade by itself, and gentle vinblastine and prednisone is kept for multiple bone lesions or lesions near the brain."@en ;
  schema:url <https://onco.cc/cancers/lch-single-system/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis> ;
  schema:citation <https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq>, <https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/lch-multisystem/>, <https://onco.cc/cancers/langerhans-cell-histiocytosis/>, <https://onco.cc/cancers/rosai-dorfman-disease/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/active-surveillance/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/cobimetinib/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/lch-iii/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/>, <https://onco.cc/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/>, <https://onco.cc/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/> ;
  onco:pipeline <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/trials/lch-iii/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/technologies/kinase-inhibitors/> .